Heterobicyclic carboxamides as inhibitors for kinases

US8242125B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Gerald D. Artman, III · Asbury, US
• Jason Matthew Elliott · Blue Bell, US
• Nan Ji · Arlington, US
• Donglei Liu · Cambridge, US
• Fupeng Ma · Cambridge, US
• Nello Mainolfi · Belmont, US
• Erik Meredith · Cambridge, US
• Karl Miranda · Lexington, US
• James J. Powers · Waltham, US
• Chang Rao · Cambridge, US

Key dates

• Filing date: Dec 7, 2009
• Grant date: Aug 14, 2012
• Expiry date: Oct 15, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel organic compounds of formula (I)and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.